anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses collateral-flow-activating pain-relieving ointment prepared from bock greenbrier rhizomes for treating affection by dampness. The present invention is prepared from bocThe invention discloses a meridian-activating pain-stopping Smilax bockii Warb plaster, prepared of Smilax bockii Warb, Antenoron filiorme (Thunb.)Roberty et Vautier, Anemone flaccida Fr Schmidt, Cinnk greenbrier rhizomes, longhairy antenoron roots, flaccid anemone rhizomes, narrowleaf burmann cinnamon roots and leaves, spine aralia root or branchlet and leaf, sargentgloryvine stems, falcate dolicamomum burmannii (Nees) Blume var. angustifolium (Hemsl.) Allen, Aralia armata (Wall.) Seem, Sargentgloryvine Stem, Cannabis sativa L, coral ardisia root, and rapeseed oil in a certain weight proportihos roots or leaves, coral ardisia roots, and rapeseed oil according to certain weight proportion. The present invention has the advantages of low cost, reasonable formula, simple preparation, convenion; it has characters of low cost, reasonable formula, fast curing, good curative effect, no side effect, etc; and these drugs cooperate to be able to effectively dispel the wind and remove damp, stiment use, fast cure, good curative effects, high safety and reliability and no side effects. The drugs are combined to perform the synergistic function of the efficacy of each drug, and thus, the preseulate the circulation of the blood and cause the muscles and joints to relax, and promote the blood circulation and stop pain; and it is applied mainly to curing traumatic injury, traumatic gall, softnt invention can effectively dispel wind and eliminate dampness, relieve rigidity of muscles and activate collatevals, and promote blood circulation to relieve pains. The present invention is mainly u tissue injury, rheumatic arthritis, atrophic arthritis, etc, and the curative effect is very good.                                                                                                     sed for treating injuries from falls, painful swellings from falls, sprain painful swellings, soft tissue contusion, rheumatic and atrophic arthritis, lumbocrural pains and arthralgia, and sprain pains in muscles and bones with very good therapeutic effects.
All participants received oral administration of extended-release capsules IPX203 dosing regimen that was determined at the end of the IPX203 dose conversion period of Study IPX203-B16-02 (NCT03670953) for nine months of open-label therapy. The dose and dosing frequency was determined by the investigator to achieve the optimal balance of efficacy and safety.
BACKGROUND: Knowledge of predictors of cognitive frailty (CF) trajectories is required to develop preventive strategies to delay or reverse the progression from CF to dementia and other adverse outcomes. This 2-year prospective study aimed to investigate factors affecting the progression and improvement of CF in older Taiwanese adults.
METHODS: In total, 832 community-dwelling people aged ≥ 65 years were eligible. Fried's five frailty criteria were used to measure prefrailty and frailty, while cognitive performance was assessed by the Clinical Dementia Rating and Mini-Mental State Examination. Each component of reversible CF and potentially reversible CF was assigned a score, with a total score ranging 0 to 5 points. Two annual follow-up CF assessments were conducted. The group-based trajectory model was applied to identify latent CF trajectory groups, and a multinomial logistic regression was used to examine relationships of explanatory variables with CF trajectories.
RESULTS: According to data on 482 subjects who completed the two annual follow-ups, three CF trajectories of robust, improvement, and progression were identified. After adjusting for the baseline CF state, CF progression was significantly associated with an older age (odds ratio [OR] = 1.08; 95% confidence interval [CI], 1.02 ~ 1.14), a lower Tinetti balance score (OR = 0.72; 95% CI, 0.54 ~ 0.96), a slower gait (OR = 0.98; 95% CI, 0.97 ~ 0.99), and four or more comorbidities (OR = 2.65; 95% CI, 1.19 ~ 5.90), while CF improvement was not significantly associated with any variable except the baseline CF state. In contrast, without adjusting for the baseline CF state, CF progression was significantly associated with an older age, female sex, balance scores, gait velocity, regular exercise, the number of comorbidities, and depression, while CF improvement was significantly associated with female sex, balance scores, and the number of comorbidities.
CONCLUSIONS: The baseline CF state, an older age, poorer balance, slower gait, and a high number of comorbidities may contribute to CF progression, while the baseline CF state may account for associations of engaging in regular exercise and depression with CF development.
This is a prospective, randomized, non-blinded, controlled trial of high risk head and neck cutaneous squamous cell carcinomas which will compare specific outcomes between two treatment arms. Subjects are eligible patients who are sent to Zitelli \& Brodland PC for Mohs micrographic surgery of tumors that meet our high risk criteria. These patients with clinically-negative lymph node exams will either enter into the arm of nodal observation or the arm of elective management of the neck, which is currently the standard protocol per the UPMC ENT department. The patients in the observation arm will have evaluation and treatment of their lymph nodes if an abnormality is detected clinically. The primary endpoint is disease-specific survival. Secondary endpoints will include overall and disease-free survival, complications, and quality of life measures for each arm.
<P>PROBLEM TO BE SOLVED: To provide an oral medicine having efficacy for treating mainly a malignant tumor, such as cancer.  <P>SOLUTION: This oral medicine for treating the malignant tumor comprises minerals which are derived from organisms and extracted therefrom after incinerating the organisms. The minerals are obtained by preliminarily mixing many kinds of the organisms and then incinerating the mixed organisms, or obtained by preliminarily incinerating each kind of the organisms, extracting each of the minerals, and mixing each of the extracted minerals. One, two or more kinds of fishes and shellfishes, wild vegetation, sea grasses, and seaweeds are mainly used as the organisms. The medicine contains at least Ca, K, Cl, Na, Si, Mg, P, and S as the minerals, and further contains other kinds of trace elements of a wide variety. The medicine is obtained by adding a thickener given by pulverizing dried plants, a binder used for granulating the whole components, and water to the extracted minerals, then forming the mixture into particles, and drying the particles, or obtained by adding the thickener given by pulverizing the plants to the extracted minerals and then granulating the mixture.  <P>COPYRIGHT: (C)2004,JPO
Cosmetic preparations for skin and hair care are manufactured from natural plant ingredients. Every single preparation is a mixture of appropriate kinds and quantities of substances. The basic substance is zeolit, the common ones are kuzu root and ginger. These cosmetic preparations are intended for care of all types of skin and hair. Natural plant ingredients and adequate manufacturing procedure secure maintenance of all the healing properties.  Executed tests show that all of the cosmetic preparations are in concordance with legislation in the field of Common use articles. Laboratory examinations and applications have so far showed that not a single preparation causes allergic reactions known up to present, nor any other side effects/contra indications.
This is a phase II, double-blind, randomized, placebo controlled trial assessing the effects of one-time oral FMT on the composition and function of the gut microbiome compared to placebo in a population of patients with baseline CRE or VRE gut colonization. Participants will be adults who have had two consecutive positive stool cultures for VRE or CRE and meet all inclusion/exclusion criteria. Patients (N=90) will be randomized at a 1:1 ratio. Randomization will be double-blinded. Each subject will be followed for 6 months. Stool samples will be taken at baseline and from subjects weekly for 4 weeks, then every 4 weeks for 8 weeks, then at 6 months regardless of treatment group. All patients will be asked to complete a stool diary
In order to assess for any non-specific effects of spending non-eating disorder driven time with family, adolescents in the CRT+ Contact Control condition will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). We refer to this condition as CRT + Family Fun Time (CRT+FFT). Adolescents will be asked to complete a series of fun tasks (some standardized, some are choice driven) with their parents. During these sessions, they will not be permitted to discuss CRT or the eating disorder.
People who recently became infected with HIV often have a high level of the virus and may be highly infectious. If they have sex (especially anal intercourse) without condoms soon after they have been infected with HIV, there is a great chance that they may transmit the virus to others. When they learn of their HIV infection, some but not all men change sexual behaviors so as not to infect their partner(s) with HIV. Possible reasons for such behavior change include increase or decrease in drug use and what is going on within their sexual partnerships. A study that tracks men with recent HIV infection and their partners over time can provide information key to stopping further spread of HIV given that sexual behaviors can vary over time, especially during this most infectious period.

This study will look at how likely it is for HIV infection to be spread among partner types over time by recently HIV-infected men and their partners. The study will compare behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. It will allow a study of sexual partnerships by actively recruiting sexual partners. We will also focus on the role of drug use, especially methamphetamine and how it changes behaviors over time. We will especially look at how different sex partners affects one's drug use and increases or decreases HIV transmission. The study will enroll 150 recently HIV-infected men who have sex with men and follow them for a year. In addition, up to 6 sexual partners of each recently HIV infected individual will be recruited and followed for a year. Some sexual partners will be HIV negative and some HIV positive. We will use their HIV status to compare behaviors over time in the group and between partners of the same status and partners of a different status. The results will be used in special formulas that will allow for a better understanding of behavior change by men with recent HIV infection. This new information will be key for designing new ways to target risk reduction for recently HIV-infected men.
The invention discloses a traditional Chinese medicine composite for treating rhinitis and a preparation method of the traditional Chinese medicine composite for treating rhinitis. The preparation method comprises the following steps that: a, the following ingredients in parts by weight: centipeda minima, fructus forsythiae, radix asteris, fructus citri, magnolia flowers, radix cynanchi atrati, Chinese tamarisk twigs and erigeron canadensis L. are prepared to 60-mesh powder and mixed uniformly; 75% alcohol is added according to a ratio of material to liquor of 1:8; reflux extraction for 2h is conducted two times; two times of reflux liquid are combined, and concentrated to an extractive with the relative density of 1.28-1.30 (35 degrees); and b, the extractive in Step a is dried and ground to 200-mesh powder A; mulberry fruits in parts by weight are prepared to 100-mesh powder B; and the powder A and the powder B are mixed uniformly and put in capsules. A patient takes 4 capsules every time, 3 times daily. According to the preparation method, the raw materials are combined and the synergistic effect of various ingredients is outstanding; the traditional Chinese medicine composite has efficacies of expelling wind, opening orifices, nourishing yin and blood, eliminating stasis to subdue swelling, dispelling wind and detoxicating, and has outstanding effect on rhinitis treatment. In addition, a preparation process of the traditional Chinese medicine composite is simple. Particularly, the traditional Chinese medicine composite has no toxic or side effect.
Anorexia nervosa (AN) is a serious and persistent psychiatric illness. Many individuals with AN cycle between stages of remission (i.e., relapse), with research documenting that cognitive remission generally lags behind nutritional/weight restoration. Yet, little is known about which mechanisms promote movement from partial remission in AN (defined as nutritional, but not cognitive, recovery) to full remission. Fear-based processes, including avoidance and approach behaviors, likely contribute to the persistence of cognitive-behavioral AN symptoms after nutritional restoration. The current study used intensive longitudinal data to characterize these processes during partial remission (N = 41 participants with partially remitted AN; 4306 total observations). We aimed to a) characterize frequency of fear-based processes in real-time, b) investigate associations across fear-based processes and behavioral urges, and c) test if real-time associations among symptoms differed across commonly feared stimuli (e.g., food, social situations). On average, participants endorsed moderate fear and avoidance, with weight-gain fears rated higher than other feared stimuli. Momentary fear, avoidance, approach, and distress were all positively associated with AN behavior urges at one time-point and prospectively. Central symptoms and symptom connections differed across models with different feared stimuli. These findings provide empirical support for the theorized fear-avoidance-urge cycle in AN, which may contribute to the persistence of eating pathology during partial remission. Fear approach may be associated with temporary increases in urges, which should be considered during treatment. Future research should explore these associations in large, heterogeneous samples, and test the effectiveness of exposure-based interventions during partial remission.
Fast Track Treatment includes many elements recommended by the ERAS Society for cardiac surgery(1). Since November 2005, we are running a specialized post anesthetic care unit (PACU) in our tertiary, university affiliated high-volume heart centre. In our concept, we are bypassing ICU admission completely. The patients are transferred from the operation room to the recovery room, extubated there within a short time, stabilized and transferred on the same day to intermediate care (IMC). Ideally, the patient will be transferred to the normal ward on the first postoperative day. The fast-track concept was initially applied to pre-selected elective patients undergoing low-risk operations. However, promising outcomes led to a more widespread utilization with more complex procedures. The aim of this study is to analyse the evolutions within the fast-track protocol over a period of 15 years (from November 2005 to December 2020).
Mammalian melanin-concentrating hormone (MCH) is isolated from rat tissue, purified and characterized. These MCH peptides are useful for treating skin disorders, for suppressing the proliferation of skin tumor cells, such as melanomas in mammals, and for modulating the secretion of ACTH. Generally, peptides are provided which have formula (I), or which are naturally occuring homologs of the peptide with said formula. The peptides which are the naturally occurring MCH homologs of mammalian species other than rat can also be obtained using the materials disclosed, as demonstrated specifically with human MCH, which is found to have the same structure as rat MCH. Also disclosed are the amino acid sequences of, and the nucleotide sequences of the cDNAs which encode, the putative precursors of rat MCH and human MCH. These precursors may also include one or more biologically active peptides N-terminally of the mature MCH's. Among these peptides, which are thought to be formed from the MCH precursors, are the peptides with the sequence H-Glu-Ile-Gly-Asp-Glu-Glu-Asn-Ser-Ala-Lys-Phe-Pro-Ile-NH2, which is cross-reactive with antibodies against alpha-MSH and CRF, and the peptides with the sequence H-Gly-XNGE-Phe-Pro-Ala-Glu-Asn-Gly-Val-Gln-Asn-Thr-Glu-Ser-Thr-Gln-Glu-OH, wherein XNGE is Pro-Ala-Val or Ser-Val-Ala, which is cross-reactive with antibodies against GRF.
Start to administer Tenofovir treatment 300mg PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
In the first group, according to Lewit's post-isometric relaxation (Muscle energy technique) method, scalene (anterior / medius / posterior), levator scapula, sternocleidomastoid, trapezius, pectoral muscles, serratus anterior and latismus dorsi muscles are set 3 days a week ( Each set includes three repetitions) The treatment will be applied for 4 weeks. The hypertonic muscle will be taken to the first point that resists movement without straining. The patient will be asked to perform an isometric contraction for 7 seconds, corresponding to 20% of the maximum isometric contraction force where the restriction is felt. After the application, the patient will be asked to exhale and relax completely. 30 seconds will be waited for each stretching and then the neck will be taken back to the barrier point and three repetitions per session will be performed.
BACKGROUND: A few studies have suggested that light at night (LAN) exposure, i.e. lighting during night hours, may increase dementia risk. We evaluated such association in a cohort of subjects diagnosed with mild cognitive impairment (MCI).
METHODS: We recruited study participants between 2008 and 2014 at the Cognitive Neurology Clinic of Modena Hospital, Northern Italy and followed them for conversion to dementia up to 2021. We collected their residential history and we assessed outdoor artificial LAN exposure at subjects' residences using satellite imagery data available from the Visible Infrared Imaging Radiometer Suite (VIIRS) for the period 2014-2022. We assessed the relation between LAN exposure and cerebrospinal fluid biomarkers. We used a Cox-proportional hazards model to compute the hazard ratio (HR) of dementia with 95% confidence interval (CI) according to increasing LAN exposure through linear, categorical, and non-linear restricted-cubic spline models, adjusting by relevant confounders.
RESULTS: Out of 53 recruited subjects, 34 converted to dementia of any type and 26 converted to Alzheimer's dementia. Higher levels of LAN were positively associated with biomarkers of tau pathology, as well as with lower concentrations of amyloid β1-42 assessed at baseline. LAN exposure was positively associated with dementia conversion using linear regression model (HR 1.04, 95% CI 1.01-1.07 for 1-unit increase). Using as reference the lowest tertile, subjects at both intermediate and highest tertiles of LAN exposure showed increased risk of dementia conversion (HRs 2.53, 95% CI 0.99-6.50, and 3.61, 95% CI 1.34-9.74). In spline regression analysis, the risk linearly increased for conversion to both any dementia and Alzheimer's dementia above 30 nW/cm2/sr of LAN exposure. Adding potential confounders including traffic-related particulate matter, smoking status, chronic diseases, and apolipoprotein E status to the multivariable model, or removing cases with dementia onset within the first year of follow-up did not substantially alter the results.
CONCLUSION: Our findings suggest that outdoor artificial LAN may increase dementia conversion, especially above 30 nW/cm2/sr, although the limited sample size suggests caution in the interpretation of the results, to be confirmed in larger investigations.
Total Body Irradiation:

In a randomized, placebo-controlled, double-blind trial in 20 patients, 8 mg of ondansetron administered 1.5 hours before each fraction of radiotherapy for 4 days was significantly more effective than placebo in preventing vomiting induced by total body irradiation. Total body irradiation consisted of 11 fractions (120 cGy per fraction) over 4 days for a total of 1,320 cGy. Patients received 3 fractions for 3 days, then 2 fractions on Day 4. 

Single High-Dose Fraction Radiotherapy:

In an active-controlled, double-blind trial in 105 patients receiving single high-dose radiotherapy (800 to 1,000 cGy) over an anterior or posterior field size of greater than or equal to 80 cm2 to the abdomen, ondansetron was significantly more effective than metoclopramide with respect to complete control of emesis (0 emetic episodes). Patients received the first dose of ondansetron (8 mg) or metoclopramide (10 mg) 1 to 2 hours before radiotherapy. If radiotherapy was given in the morning, 8 mg of ondansetron or 10 mg of metoclopramide was administered in the late afternoon and repeated again before bedtime. If radiotherapy was given in the afternoon, patients took 8 mg of ondansetron or 10 mg of metoclopramide only once before bedtime. Patients continued the doses of oral medication three times daily for 3 days.

Daily Fractionated Radiotherapy:

In an active-controlled, double-blind trial in 135 patients receiving a 1- to 4-week course of fractionated radiotherapy (180 cGy doses) over a field size of greater than or equal to 100 cm2 to the abdomen, ondansetron was significantly more effective than prochlorperazine with respect to complete control of emesis (0 emetic episodes). Patients received the first dose of ondansetron (8 mg) or prochlorperazine (10 mg) 1 to 2 hours before the first daily radiotherapy fraction, with subsequent 8-mg doses approximately every 8 hours on each day of radiotherapy.
Group 1 (control: tailored hypocaloric diet and exercise advised): patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant. Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
TG01 is mixed with adjuvant QS-21 and given subcutaneously. After six administrations given once every two weeks of TG01 vaccine (+adjuvant QS-21) over 12 weeks during weeks 1,3,5,7,9,11, \[priming/booster phase\]), the treatment will then switch to a maintenance phase of TG01 vaccine (+adjuvant QS-21) once every 8 weeks for up to 51 weeks: The maintenance treatments will occur during weeks 19, 27, 35, 43, and 51. Maintenance treatments will end on week 51 or at the time of disease recurrence; whichever is the earliest.
As soon as the diagnosis of chronic GVHD requiring systemic immunosuppressive therapy is confirmed, patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.Rituximab should be administered within 14 days of starting prednisone. Follow-up dates for response assessment and laboratory tests relate to the date of Rituximab infusion.Patients having a partial response after the 1st cycle of Rituximab will be eligible to receive a second cycle of 4 infusions during 4 weeks. A delay of 8 weeks (from the first infusion of Rituximab) will be observed between the two cycles of Rituximab therapy.Patients who relapse after an initial treatment with one cycle of 4 infusions of Rituximab will be eligible to receive a second cycle of Rituximab therapy.